Study on suitable analysis method for HIV-1 non-catalytic integrase inhibitor.

Area of Science:

• Virology
• Drug Discovery
• HIV Research

Background:

• Integrase (IN) is crucial for HIV replication, enabling viral genome integration into host DNA.
• Integrase strand transfer inhibitors (INSTI) are common HIV drugs, but mutations can cause resistance.
• Next-generation non-catalytic integrase inhibitors (NCINI) are developed to overcome INSTI resistance.

Purpose of the Study:

• To compare the antiviral activity of INSTI and NCINI using different assay methods.
• To evaluate the suitability of p24 ELISA and TZM-bl luciferase systems for screening integrase inhibitors.

Main Methods:

• Compared INSTI and NCINI activity using p24 ELISA (MT2 cells) and TZM-bl luciferase assay (TZM-bl cells).
• Cells were infected with HIV-1 AD8 strain and treated with serially diluted drugs.
• Performed transfer inhibition and 3'-processing inhibition assays to analyze inhibitor properties.

Main Results:

• Both INSTI and NCINI showed significant p24 reduction in MT2 cells.
• NCINI demonstrated no antiviral activity in the TZM-bl luciferase system.
• The TZM-bl assay is unsuitable for screening NCINI targeting the second round of HIV-1 replication.

Conclusions:

• The TZM-bl luciferase system is not ideal for preliminary screening of NCINI.
• Recommend using p24 ELISA or reverse transcription activity assays for NCINI screening.
• Accurate drug efficacy assessment requires analytical methods aligned with underlying mechanisms.